查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2009216

基因型鉴定市场规模、份额、趋势和预测：按产品/服务、技术、应用、最终用户和地区划分，2026-2034 年

Genotyping Market Size, Share, Trends and Forecast by Product and Service, Technology, Application, End User, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3个工作天内

价格

2025年全球基因型鉴定市场规模为245亿美元，预计2034年将达到642亿美元，2026年至2034年的复合年增长率（CAGR）为10.96%。目前，北美市场主导地位，2025年市占率超过39.80%。推动此市场成长的因素包括：基因型鉴定在精准医疗领域的应用日益广泛、在农业和畜牧业改良领域的应用范围不断扩大，以及消费者对直接检测服务的需求不断增长。此外，研发投入的增加以及消费者对遗传健康资讯的接受度不断提高，也进一步推动了基因型鉴定市场份额的成长。

全球市场的主要驱动力是精准医疗和个人化疗法的日益普及。此外，次世代定序(NGS) 和先进分子诊断技术的整合也是推动市场成长的重要因素。 2025 年 9 月，Illumina 推出了 Illumina Protein Prep，这是一种基于 NGS 的蛋白质体学检测方法，能够检测 9,500 个人类蛋白质标靶。这是目前 NGS 分析中可检测标靶数量最多的产品。早期试验分别使用 6K 检测方法处理了 30,000 个检体，使用 9.5K 检测方法处理了 6,000 个检体。英国基因组学公司 (Genomics England) 报告称，使用该平台后，罕见疾病病例的诊断率提高了 7.5%。此外，製药和生技公司加大对标靶药物研发的投入也是市场成长的关键驱动因素。同时，基因型鉴定在农业生物技术和畜牧管理领域的应用日益广泛，也扩大了基因分型的应用范围。最后，随着人们健康意识的提高，消费者基因检测套组的日益普及也为市场创造了盈利的商机。

美国作为重要的区域市场脱颖而出，其成长主要得益于遗传疾病盛行率的上升以及对早期检测策略的高度重视。此外，生物技术基础设施和先进实验室设施的大量投资也进一步推动了市场发展。 2025年1月，Complete Genomics宣布在圣荷西开设一家占地10,115平方英尺的生产工厂，随后于2024年在弗雷明汉设立客户经验中心，从而在美国建立首个NGS供应链。圣荷西工厂已开始生产可连续运作12小时的DNBSEQ-G99RS定序仪，并已获得NRTL认证。此外，与NVIDIA、Eurofins、AdvancedDx和seqWell的合作进一步扩展了美国的基因组学网络。消费者对祖源检测和个人化健康计画日益增长的需求也是市场成长的关键驱动因素。大型製药公司及其对药物基因体学的关注也为强大的商业产品线的形成做出了贡献。

基因型鉴定市场趋势：

医疗成本上升与预防基因体学的推广

慢性疾病带来的经济负担持续影响全球医疗保健策略，也为基因型鉴定解决方案创造了新的机会。报告显示，预计2030年，全球整体慢性疾病的估计费用将达到47兆美元，凸显了早期更有效预防的迫切性。基因型鉴定能够进行预测性风险评估，使个人能够在疾病进展到需要昂贵的临终治疗之前了解自身的易感性。随着各国政府、保险公司和医疗服务提供者寻求应对不可持续支出的方法，基因型鉴定技术正被整合到精准医疗计画和倡议计画中。这种转变不仅将降低未来的医疗保健成本，还将加强基因检测公司在製定人群健康策略中的作用。

多种慢性疾病正在推动对个人化医疗的需求。

在美国，多种疾病重迭的高发生率为个人化基因组服务的应用创造了有利环境。数据显示，42%的美国人患有两种或两种以上的慢性疾病，12%的人患有至少五种慢性疾病，显示对个别化介入的需求日益增长。传统的治疗方案往往未能充分考虑影响药物疗效和疾病进展的遗传差异。基因型鉴定透过识别可能影响药物反应和多种疾病併发症风险的突变，提供明确的指南。医疗服务提供者正开始利用这些资讯来优化复杂疾病患者的治疗方法。随着这一趋势的加速发展，对经济高效且易于使用的基因型鉴定平台的需求预计将会增加，尤其是在基层医疗和专科诊所。

政府对医疗保健的投资正在促进基因组学的发展。

作为医疗体系现代化大规模投资的一部分，基因组学在国家医疗政策中日益受到重视。据印度品牌资产基金会（Brand 股权 Foundation of India）称，印度政府在2025-2026财年联邦预算中为医疗卫生领域拨款99,858卡罗尔印度卢比（约合115亿美元），这清晰地表明了其加强基础设施和研究能力的意图。基因型鉴定服务将直接受益于这些公共投资，这些投资特别专注于数位健康、预防医学和生物技术发展。透过促进公共机构、生技公司和诊断服务提供者之间的合作，这笔资金将有助于降低基因型鉴定广泛应用的门槛。印度的努力是全球更大趋势的一部分，各国政府都在增加对精准医疗的投入，以应对日益严重的慢性病负担和不断增长的预防医学解决方案需求。

目录

第一章：序言

第二章：调查方法

  • 调查目的
  • 相关利益者
  • 数据来源
    • 主要讯息
    • 次要讯息
  • 市场估值
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章执行摘要

第四章：引言

第五章：全球基因型鉴定市场

  • 市场概览
  • 市场表现
  • 新冠疫情的影响
  • 市场预测

第六章 市场区隔：依产品及服务划分

  • 装置
  • 试剂和试剂盒
  • 软体服务

第七章 市场区隔：依技术划分

  • 聚合酵素链锁反应（PCR）
  • 毛细管电泳
  • 微阵列
  • 顺序
  • 质谱分析
  • 其他的

第八章 市场区隔：依应用领域划分

  • 药物基因体学
  • 诊断及个人化医疗
  • 农业生物技术
  • 动物遗传学
  • 其他的

第九章 市场区隔：依最终用户划分

  • 製药和生物製药公司
  • 诊断与研究实验室
  • 学术机构
  • 其他的

第十章 市场区隔：依地区划分

  • 北美洲
    • 我们
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第十一章 SWOT 分析

第十二章：价值链分析

第十三章：波特五力分析

第十四章：价格分析

第十五章 竞争格局

  • 市场结构
  • 主要企业
  • 主要企业简介
    • Agilent Technologies Inc.
    • Bio-Rad Laboratories Inc.
    • Danaher Corporation
    • Eurofins Scientific SE
    • F. Hoffmann-La Roche AG
    • Illumina Inc.
    • Laboratory Corporation of America Holdings
    • Qiagen NV
    • Standard BioTools Inc.
    • Thermo Fisher Scientific Inc.
Product Code: SR112026A5815

The global genotyping market size was valued at USD 24.5 Billion in 2025 . Looking forward, the market is projected to reach USD 64.2 Billion by 2034 , exhibiting a CAGR of 10.96% during 2026-2034 . North America currently dominates the market, holding a significant market share of over 39.80% in 2025 . The market is driven by the increasing use of genotyping in precision medicine, the expanding applications in agriculture and livestock improvement, and the rising demand for direct-to-consumer testing services. With growing investments in research and technological innovations, along with expanding consumer adoption of genetic health insights, these factors are further augmenting the genotyping market share.

The global market is primarily driven by the rising adoption of precision medicine and personalized therapies. In line with this, the growing integration of next-generation sequencing and advanced molecular diagnostics is also providing an impetus to the market. In September 2025, Illumina launched Illumina Protein Prep, an NGS-based proteomics assay capable of measuring 9,500 unique human protein targets, the highest content available with an NGS readout. Early access studies processed 30,000 samples with the 6K assay and 6,000 with the 9.5K assay, with Genomics England reporting a 7.5% increase in diagnostic yield for rare disease cases using the platform. Moreover, the increasing investments by pharmaceutical and biotechnology companies in targeted drug discovery are also acting as a significant growth-inducing factor for the market. In addition to this, the expanding use of genotyping in agricultural biotechnology and livestock management is resulting in a wider range of applications. Besides this, the rising popularity of direct-to-consumer genetic testing kits due to increasing health consciousness is creating lucrative opportunities in the market.

The United States stands out as a key regional market, which is primarily driven by the growing prevalence of genetic disorders and the strong focus on early detection strategies. In line with this, significant investments in biotechnology infrastructure and advanced laboratory facilities are also providing an impetus to the market. In January 2025, Complete Genomics announced it had opened a 10,115 sq. ft. manufacturing facility in San Jose and a Customer Experience Center in Framingham in 2024, establishing its first U.S. NGS supply chain. The San Jose site began producing DNBSEQ-G99RS sequencers with a 12-hour run time and earned NRTL certification, while collaborations with NVIDIA, Eurofins, AdvancedDx, and seqWell expanded its U.S. genomic network. Moreover, the rising consumer demand for ancestry testing and personalized wellness programs is also acting as a significant growth-inducing factor for the market. In addition to this, the presence of leading pharmaceutical companies and their focus on pharmacogenomics is resulting in a strong commercial pipeline.

GENOTYPING MARKET TRENDS:

Rising Healthcare Costs and the Push for Preventive Genomics

The financial weight of chronic diseases continues to shape global healthcare strategies, creating new opportunities for genotyping solutions. According to reports, the estimated cost of chronic disease is expected to reach USD 47 Trillion worldwide by 2030, a figure that underscores the urgency for earlier and more effective prevention. Genotyping allows for predictive risk profiling, enabling individuals to understand their predispositions before illnesses progress to costly, late-stage treatments. As governments, insurers, and healthcare providers search for ways to offset unsustainable expenditures, genotyping technologies are being integrated into precision medicine programs and wellness initiatives. This shift not only reduces future healthcare spending but also strengthens the role of genetic testing companies in shaping population health strategies.

Multiple Chronic Conditions Driving Personalized Care Demand

In the United States, the prevalence of overlapping health conditions has created a fertile environment for the adoption of personalized genomic services. Data indicates that 42% of Americans manage two or more chronic conditions, and 12% live with at least five, pointing to a growing need for tailored interventions. Traditional treatment protocols often fail to account for the genetic differences influencing drug efficacy and disease progression. Genotyping offers clarity by identifying variations that can impact responses to medications or risks of complications across multiple conditions. Healthcare providers are beginning to use this information to fine-tune therapies for patients with complex health profiles. As this trend accelerates, demand for cost-effective and accessible genotyping platforms is expected to rise, particularly in primary care and specialty clinics.

Government Investments in Healthcare Fueling Genomics Expansion

National health policies are increasingly prioritizing genomics as part of larger investments in modernizing healthcare systems. According to India Brand Equity Foundation, the government has allocated Rs. 99,858 crore (USD 11.50 Billion) to the healthcare sector in the Union Budget 2025-26, signaling a clear intent to strengthen infrastructure and research capacity. Genotyping services stand to benefit directly from these public investments, particularly through initiatives focused on digital health, preventive care, and biotechnology development. By fostering collaborations between public institutions, biotech firms, and diagnostic providers, such funding helps lower the barriers to widespread adoption. India's commitment is part of a larger global pattern, where governments are channeling resources into precision medicine to manage both rising chronic disease burdens and the growing demand for preventive health solutions.

GENOTYPING INDUSTRY SEGMENTATION:

Analysis by Product and Service:

  • Instruments
  • Reagents and Kits
  • Software and Services

Reagents and kits stand as the largest component in 2025, holding around 48.9% of the market. Their dominance is largely due to recurring demand, as laboratories and testing facilities must continually procure reagents for each test conducted. This makes them a consistent revenue stream compared to one-time purchases of instruments. Furthermore, the growing number of diagnostic centers, rising adoption of direct-to-consumer genetic testing, and increased research activity in pharmacogenomics and agricultural genetics are fueling higher consumption of kits. The availability of standardized, user-friendly, and automation-compatible reagent systems has further simplified genotyping, expanding accessibility across both advanced labs and smaller testing setups. By enabling high-throughput testing and supporting cost efficiency, reagents and kits not only streamline laboratory processes but also directly contribute to scaling up global genotyping applications and accelerating market growth.

Analysis by Technology:

  • Polymerase Chain Reaction (PCR)
  • Capillary Electrophoresis
  • Microarray
  • Sequencing
  • Mass Spectrometry
  • Others

Polymerase Chain Reaction (PCR) leads the market with around 34.8% of market share in 2025, due to its long-established reliability, cost-effectiveness, and widespread adoption. PCR enables rapid amplification of DNA, allowing even small genetic variations to be detected with high accuracy. Its dominance is further strengthened by its compatibility with various downstream applications, including disease diagnostics, forensic testing, and agricultural research. The method remains a preferred choice in clinical laboratories and research institutions as it requires relatively simple instrumentation while delivering highly reproducible results. Additionally, PCR has seen continuous technological refinement, such as the introduction of real-time and digital PCR, which provide greater sensitivity and quantification capabilities. Its cost-effectiveness makes it especially attractive in emerging economies, while its adaptability to both small-scale studies and large-scale population screening ensures broad usage.

Analysis by Application:

  • Pharmacogenomics
  • Diagnostics and Personalized Medicine
  • Agricultural Biotechnology
  • Animal Genetics
  • Others

Diagnostics and personalized medicine lead the market with around 33.8% of market share in 2025, driven by the growing need for targeted treatments and individualized patient care. The ability to identify genetic variations that influence disease susceptibility, treatment response, and drug metabolism has transformed medical practice. This application area is gaining dominance because it directly addresses the global rise in chronic and complex diseases, where traditional one-size-fits-all treatments are often ineffective. Healthcare systems are increasingly investing in genomic testing to enable earlier diagnosis, better therapeutic alignment, and improved patient outcomes. Moreover, pharmaceutical companies are leveraging genotyping in clinical trials to stratify patients and develop precision therapies, further embedding it into the medical pipeline. Consumer demand for personalized health insights, including ancestry and wellness testing, also feeds into this trend.

Analysis by End User:

  • Pharmaceutical and Biopharmaceutical Companies
  • Diagnostics and Research Laboratories
  • Academic Institutes
  • Others

Pharmaceutical and biopharmaceutical companies represent a major end-user segment, as they utilize genotyping to identify genetic markers linked to drug response and disease susceptibility. This enables them to design precision therapies and accelerate clinical trial efficiency. The integration of genotyping into early-stage drug development helps reduce costs and improve approval rates, making it a vital tool for commercial success. With rising investment in personalized medicine and biologics, these companies are expanding demand for advanced genotyping platforms to strengthen their research pipelines.

Diagnostics and research laboratories form a crucial segment, as they directly translate genotyping innovations into routine healthcare and specialized investigations. These facilities rely on genotyping for early disease detection, pathogen identification, and risk profiling, enabling better patient outcomes. Their role extends to high throughput testing in clinical diagnostics, cancer screening, and infectious disease monitoring. Continuous technological upgrades in laboratory settings further strengthen adoption, ensuring reliable and cost-effective results. By bridging innovation with practical medical application, diagnostics and research laboratories are key drivers of widespread genotyping market growth worldwide.

Academic institutes contribute significantly to the genotyping market by advancing basic research, validating novel methodologies, and training the next generation of scientists. They often collaborate with government agencies, biotech firms, and healthcare providers to develop innovative applications in genomics. Genotyping platforms in academic labs are widely used for studying genetic variation, evolutionary biology, and population health, fostering new discoveries that eventually transition into clinical or commercial use. By supporting innovation and building skilled expertise, academic institutes help ensure sustained progress and long-term growth within the genotyping market.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America accounted for the largest market share of over 39.80%, supported by its advanced healthcare infrastructure, strong research ecosystem, and high healthcare spending. The United States leads within the region due to widespread adoption of personalized medicine, extensive government and private funding for genomics research, and the presence of leading biotechnology and pharmaceutical firms. Canada also contributes meaningfully with its emphasis on population-scale genetic studies and integration of genomics into public healthcare. The region's strong regulatory frameworks, combined with robust insurance coverage for genetic testing, further promote accessibility and adoption. Additionally, North America is home to major technology developers and reagent suppliers, reinforcing its dominance in product availability and innovation. With a well-established network of diagnostic laboratories, academic institutions, and biopharma companies, the region serves as a global hub for genotyping research and commercialization, ensuring continued leadership in market growth.

KEY REGIONAL TAKEAWAYS:

UNITED STATES GENOTYPING MARKET ANALYSIS

The United States accounts for 83.80% of the North America genotyping market. United States is witnessing increased genotyping adoption due to growing chronic lifestyle diseases such as obesity, cardiovascular ailments, and diabetes. For instance, 6 out of 10 Americans have one chronic disease and four out of 10 have two or more chronic diseases that account for ninety percent of the USD 4.5 Trillion annual health care costs in the nation. Rising public awareness, increasing preventive healthcare measures, and higher inclination toward personalized medicine are further driving genotyping usage. With healthcare providers focusing on precision diagnostics, genotyping is becoming integral in disease risk assessment and treatment planning. Integration of genotyping in routine clinical workflows, supported by favourable reimbursement policies, has further accelerated its acceptance. Rising prevalence of conditions requiring early detection and targeted interventions has created a strong foundation for the adoption of genotyping technologies. Healthcare infrastructure investments and continuous physician education have also improved accessibility and patient outcomes.

ASIA PACIFIC GENOTYPING MARKET ANALYSIS

Asia-Pacific is experiencing strong momentum in genotyping due to the growing number of diagnostics and research laboratories across the region. For instance, India's pharmaceutical industry ranks third globally in pharmaceutical production by volume and 14th by value, supported by a well-established domestic sector comprising approximately 3,000 drug companies and over 10,000 custom manufacturing units. As demand for accurate disease identification rises, these laboratories are increasingly deploying advanced genotyping techniques to support genomic studies, drug discovery, and molecular diagnostics. Improved funding from public and private sources has enabled laboratories to upgrade capabilities and invest in next-generation sequencing platforms. Government-supported research initiatives and medical tourism have also enhanced genotyping implementation across clinical and research settings. A surge in partnerships between academic institutions and biotechnology firms is bolstering innovation and accessibility in genotyping.

EUROPE GENOTYPING MARKET ANALYSIS

Europe is showing accelerated genotyping adoption due to the growing geriatric population that is susceptible to developing numerous medical conditions, and continual technological advancements in genotyping products. According to WHO, the population aged 60 and older is rapidly growing in the WHO European Region. In 2021, there were 215 Million; by 2030, it is projected to be 247 Million, and by 2050, over 300 Million. As older adults face a higher risk of complex diseases, genotyping is increasingly used for predictive diagnostics, pharmacogenomics, and treatment planning. At the same time, technological progress in platforms such as high-throughput sequencing and microarrays has enhanced efficiency and reduced costs. Innovations in software analytics and sample preparation workflows have made genotyping more accessible to clinicians and researchers alike. The aging population is also contributing to a rise in clinical trials and biobanking initiatives, increasing the demand for accurate genotyping.

LATIN AMERICA GENOTYPING MARKET ANALYSIS

Latin America is witnessing greater genotyping expansion, driven by growing healthcare expenditure across the region. For instance, budget allocation for Brazil's Unified Health System is expected to increase by 6.2% in 2025 . As countries increase their budgets for public health services and medical infrastructure, genotyping is becoming a prioritized tool for disease prevention, genetic screening, and personalized treatment strategies. Rising investment in laboratory modernization and clinical capabilities is enabling broader access to genotyping solutions, particularly in urban healthcare settings.

MIDDLE EAST AND AFRICA GENOTYPING MARKET ANALYSIS

Middle East and Africa are experiencing rising genotyping adoption due to growing cancer cases across the region. For instance, the Kingdom reports 27% of the GCC's total cancer cases, with an estimated 18,000 new diagnoses annually. With healthcare systems increasingly focusing on early diagnosis and targeted oncology treatments, genotyping is becoming essential in identifying genetic mutations associated with various cancers. Enhanced access to diagnostic technologies and increased awareness among healthcare providers are contributing to this trend.

COMPETITIVE LANDSCAPE:

To enhance market growth, key companies in the global genotyping market are heavily investing in technological innovation to make the process faster, more accurate, and cost-effective. A primary focus is on developing high-throughput, automated systems that can process vast numbers of samples efficiently, catering to the demands of large-scale pharmaceutical and academic research. They are also expanding the applications of genotyping beyond traditional genomics into areas like pharmacogenomics for personalized medicine, agricultural biotechnology, and direct-to-consumer genetic testing. Furthermore, strategic collaborations with research institutions and pharmaceutical companies are common, helping to co-develop new applications and expand their global reach. By making the technology more accessible and applicable, these players are driving its adoption across diverse fields.

The report provides a comprehensive analysis of the competitive landscape in the genotyping market with detailed profiles of all major companies, including:

  • Agilent Technologies Inc.
  • Bio-Rad Laboratories Inc.
  • Danaher Corporation
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche AG
  • Illumina Inc.
  • Laboratory Corporation of America Holdings
  • Qiagen N.V
  • Standard BioTools Inc.
  • Thermo Fisher Scientific Inc.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the genotyping market?

2. What is the future outlook of the genotyping market?

3. What are the key factors driving the genotyping market?

4. Which region accounts for the largest genotyping market share?

5. Which are the leading companies in the global genotyping market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Genotyping Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product and Service

  • 6.1 Instruments
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Reagents and Kits
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Software and Services
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 Polymerase Chain Reaction (PCR)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Capillary Electrophoresis
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Microarray
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Sequencing
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Mass Spectrometry
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Pharmacogenomics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Diagnostics and Personalized Medicine
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Agricultural Biotechnology
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Animal Genetics
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Pharmaceutical and Biopharmaceutical Companies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Diagnostics and Research Laboratories
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Academic Institutes
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Agilent Technologies Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Bio-Rad Laboratories Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Danaher Corporation
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
    • 15.3.4 Eurofins Scientific SE
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
    • 15.3.5 F. Hoffmann-La Roche AG
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
    • 15.3.6 Illumina Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Laboratory Corporation of America Holdings
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
    • 15.3.8 Qiagen N.V
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
    • 15.3.9 Standard BioTools Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
    • 15.3.10 Thermo Fisher Scientific Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Genotyping Market: Major Drivers and Challenges
  • Figure 2: Global: Genotyping Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Genotyping Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Genotyping Market: Breakup by Product and Service (in %), 2025
  • Figure 5: Global: Genotyping Market: Breakup by Technology (in %), 2025
  • Figure 6: Global: Genotyping Market: Breakup by Application (in %), 2025
  • Figure 7: Global: Genotyping Market: Breakup by End User (in %), 2025
  • Figure 8: Global: Genotyping Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Genotyping (Instruments) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Genotyping (Instruments) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Genotyping (Reagents and Kits) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Genotyping (Reagents and Kits) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Genotyping (Software and Services) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Genotyping (Software and Services) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Genotyping (Polymerase Chain Reaction (PCR)) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Genotyping (Polymerase Chain Reaction (PCR)) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Genotyping (Capillary Electrophoresis) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Genotyping (Capillary Electrophoresis) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Genotyping (Microarray) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Genotyping (Microarray) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Genotyping (Sequencing) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Genotyping (Sequencing) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Genotyping (Mass Spectrometry) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Genotyping (Mass Spectrometry) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Genotyping (Other Technologies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Genotyping (Other Technologies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Genotyping (Pharmacogenomics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Genotyping (Pharmacogenomics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Genotyping (Diagnostics and Personalized Medicine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Genotyping (Diagnostics and Personalized Medicine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Genotyping (Agricultural Biotechnology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Genotyping (Agricultural Biotechnology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Genotyping (Animal Genetics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Genotyping (Animal Genetics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Global: Genotyping (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Global: Genotyping (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Global: Genotyping (Pharmaceutical and Biopharmaceutical Companies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Global: Genotyping (Pharmaceutical and Biopharmaceutical Companies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Global: Genotyping (Diagnostics and Research Laboratories) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Global: Genotyping (Diagnostics and Research Laboratories) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Global: Genotyping (Academic Institutes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Global: Genotyping (Academic Institutes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Global: Genotyping (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Global: Genotyping (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: North America: Genotyping Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: North America: Genotyping Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: United States: Genotyping Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: United States: Genotyping Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Canada: Genotyping Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Canada: Genotyping Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Asia-Pacific: Genotyping Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Asia-Pacific: Genotyping Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: China: Genotyping Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: China: Genotyping Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Japan: Genotyping Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Japan: Genotyping Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: India: Genotyping Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: India: Genotyping Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: South Korea: Genotyping Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: South Korea: Genotyping Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Australia: Genotyping Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Australia: Genotyping Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Indonesia: Genotyping Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Indonesia: Genotyping Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Others: Genotyping Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Others: Genotyping Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Europe: Genotyping Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Europe: Genotyping Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Germany: Genotyping Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Germany: Genotyping Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: France: Genotyping Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: France: Genotyping Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: United Kingdom: Genotyping Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: United Kingdom: Genotyping Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Italy: Genotyping Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Italy: Genotyping Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Spain: Genotyping Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Spain: Genotyping Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Russia: Genotyping Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 80: Russia: Genotyping Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Others: Genotyping Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 82: Others: Genotyping Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 83: Latin America: Genotyping Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 84: Latin America: Genotyping Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 85: Brazil: Genotyping Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 86: Brazil: Genotyping Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 87: Mexico: Genotyping Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 88: Mexico: Genotyping Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 89: Others: Genotyping Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 90: Others: Genotyping Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 91: Middle East and Africa: Genotyping Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 92: Middle East and Africa: Genotyping Market: Breakup by Country (in %), 2025
  • Figure 93: Middle East and Africa: Genotyping Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 94: Global: Genotyping Industry: SWOT Analysis
  • Figure 95: Global: Genotyping Industry: Value Chain Analysis
  • Figure 96: Global: Genotyping Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Genotyping Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Genotyping Market Forecast: Breakup by Product and Service (in Million USD), 2026-2034
  • Table 3: Global: Genotyping Market Forecast: Breakup by Technology (in Million USD), 2026-2034
  • Table 4: Global: Genotyping Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 5: Global: Genotyping Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 6: Global: Genotyping Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Genotyping Market: Competitive Structure
  • Table 8: Global: Genotyping Market: Key Players